Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 395

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 395
---
 in the future will be primarily to fund our operations, working capital needs, capital expenditures and other general corporate purposes. Cash Flow Summary

|                                 |     | Year Ended December 31, 
                    2024 |     |            2023 |     |              |
|:--------------------------------|:----|------------------------:|:----|----------------:|:----|-------------:|
|                                 |     |               Successor |     |       Successor |     |  Predecessor |
| (Dollars in thousands)          |     |            January 1 to 
             December 31 |     | September 28 to 
     December 31 |     | January 1 to 
 September 27 |
| Net cash provided by (used in): |     |                         |     |                 |     |              |
| Operating activities            |     |               $(24,693) |     |        $(4,022) |     |    $(17,359) |
| Investing activities            |     |                    -570 |     |              $— |     |       $(882) |
| Financing activities            |     |                  25,263 |     |          $4,022 |     |      $20,166 |

Net cash used in operating activities for the year ended December 31, 2024 (Successor), and for the periods from January 1, 2023 to September 27, 2023 (Predecessor) and September 28, 2023 to December 31, 2023 (Successor) was $24.7 million, $17.4 million, and $4.0 million, respectively, consisting primarily of the operating loss for the respective period. Net cash used in investing activities for the year ended December 31, 2024 (Successor), and for the periods from January 1, 2023 to September 27, 2023 (Predecessor) and September 28, 2023 to December 31, 2023 (Successor) was $570 thousand, $882 thousand and zero, respectively. It consisted exclusively of purchases of property and equipment. Net cash provided by financing activities for the year ended December 31, 2024 (Successor), and for the periods from January 1, 2023 to September 27, 2023 (Predecessor) and September 28, 2023 to December 31, 2023 (Successor) was $25.3